Percentage of Revenue from Patented Products KPI

Percentage of Revenue from Patented Products is a critical KPI that reflects a company's innovation and market positioning.

It directly influences financial health, operational efficiency, and overall ROI metrics.

A higher percentage indicates successful monetization of intellectual property, leading to improved profit margins and competitive positioning.

Conversely, a lower percentage may suggest reliance on generic products, which can hinder growth.

Tracking this KPI enables organizations to align their strategic initiatives with market demands and innovation goals.

Companies should aim for a target threshold that reflects industry standards and their unique business outcomes.

How Percentage of Revenue from Patented Products Connects to Your Strategy

Percentage of Revenue from Patented Products appears in one KPI group, Intellectual Property Strategy, where it ranks sixth among fifty-one metrics. Above it sit Cost of IP Protection, IP Strategy Alignment with Business Goals, IP Licensing Revenue, Number of Patents Filed, and Number of Patents Granted. Below it, IP Portfolio Strength and Innovation to IP Conversion Rate. The ordering rewards a literal reading: the KPI group puts the cost of holding a portfolio and the activity that builds it above the revenue that justifies either. This is the metric where all of that either pays or does not.

Its balanced scorecard placement is financial, and among the financial metrics in this KPI group it is by far the slowest. Number of Patents Filed records this year's intent. Number of Patents Granted records an examiner's decision on work done years earlier. Revenue standing behind those grants arrives later again, and then stops on a schedule fixed at filing. So it is a lagging confirmation with a known expiry date, which is unusual. Most lagging metrics do not come with a calendar date on which they will fall regardless of how well the team performs.

The clearest tension in this KPI group is with IP Licensing Revenue, ranked third. Same asset, two ways to monetize it. Hold exclusivity and the covered product carries the revenue, which this metric counts. License the patent out, non-exclusively in particular, and the money arrives as licensing income while the exclusivity that protected the product's price erodes. A team pushing hard on IP Licensing Revenue can depress this metric while the portfolio is doing more work rather than less. The two belong in the same review, read together.

There is a second tension, with Cost of IP Protection at the top of the group. The cheapest way to move this number is not invention. It is broadening what counts as patented: file narrow, inexpensive claims that read on products already selling, and the numerator grows without the portfolio getting any stronger. Cost of IP Protection and IP Portfolio Strength are what catch that, since cost per asset climbs while portfolio quality does not. The group's own OKR guidance makes the same argument, favoring portfolio quality over raw patent counts.

Innovation to IP Conversion Rate, eighth in the group, is the leading indicator that eventually shows up here, with several years between the two. IP Strategy Alignment with Business Goals is the qualitative version of the claim this metric makes numerically, which is why the group's guidance names both in the same breath.

Measuring Percentage of Revenue from Patented Products in Practice

The formula divides revenue from patented products by total revenue. The denominator comes out of the ledger and is not the problem. Everything difficult lives in the numerator, in one join that no system performs for you: the link between a patent claim and a product.

That link is an assertion, made by counsel and engineering together, that a granted claim reads on a specific product as it is currently built. It is legal judgment stored as data, and it goes stale when a product is redesigned, when a claim is narrowed in prosecution, or when one is knocked out in a post-grant challenge. Build it as a real table with an owner and an effective date, joined to the item master on one side and the patent docket on the other. If the mapping lives in a spreadsheet that one person maintains, the metric is that person's opinion with a percent sign on it.

Decide what makes a product patented. A single granted claim reading on a single component is a different standard from a patent covering the invention a customer buys the product for. Either is defensible; publishing without saying which you applied is not.

Decide which statuses count. Pending applications confer no enforceable exclusivity and many never grant. Expired ones confer none either, though the product carries on selling. Patents licensed in from another owner give freedom to practice, not exclusivity, and carry a royalty. Treat owned and granted as the base, and report licensed-in and pending separately.

Decide how revenue gets allocated. A patented component inside a larger unpatented assembly is the common case, and attributing the whole assembly's revenue to it is the common error. The alternatives are a component-level allocation with a bill-of-materials or transfer-price basis, or exclusion. Bundles and platform pricing raise the same question one level up. The cleanest answer there is to reuse the standalone-selling-price allocation revenue accounting already performs, so IP and finance do not keep two conflicting views of one sale. Attached streams need their own stated policy: maintenance, consumables, and subscriptions sold alongside a patented device are usually not covered themselves, and whether that annuity inherits the device's status should be a decision rather than an accident of how someone wrote the query.

Compute by market, not globally. A patent family is granted in some jurisdictions and refused or never filed in others, so the same product is patented in one market and unpatented in another. A single flag on the product master will overstate the share. Cross revenue by destination country against the family's granted states, then roll up.

Segment by time to expiry. This is the cut most teams skip and the one that matters most. Revenue attached to families expiring inside the planning horizon is a scheduled cliff, and the metric will drop on a calendar date with no operational failure behind it. Forecast that drop and report it apart from performance.

A last distinction, because it causes real confusion. This is not a new-product vitality measure. Vitality asks what share of revenue comes from recently launched products; this asks what share stands behind enforceable exclusivity. An old product with a live patent counts here and not there. Teams that conflate the two end up puzzled that the number will not respond to the innovation program.

Common Pitfalls

Many organizations overlook the importance of a balanced patent portfolio, which can lead to missed revenue opportunities.

• Failing to invest in R&D can stifle innovation. Without continuous development, companies risk falling behind competitors who capitalize on new technologies and market trends.
• Neglecting to protect intellectual property can result in lost revenue. Companies may find their innovations copied by competitors, diminishing their market share and profitability.
• Overemphasizing short-term gains can undermine long-term strategy. Focusing solely on immediate revenue may lead to a lack of investment in future product development.
• Inadequate management reporting on patent performance can obscure insights. Without clear metrics, organizations may struggle to make data-driven decisions regarding their patent strategy.

Improvement Levers

Enhancing the percentage of revenue from patented products requires a multifaceted approach that prioritizes innovation and strategic alignment.

• Invest in R&D to foster innovation. Allocating resources to develop new patented products can enhance market differentiation and drive revenue growth.
• Conduct regular benchmarking against industry leaders. Understanding competitors' patent strategies can inform adjustments to your own approach and improve market positioning.
• Implement a robust patent management system. Streamlining processes for filing and maintaining patents can reduce costs and improve operational efficiency.
• Encourage cross-functional collaboration between R&D and marketing teams. Aligning product development with market needs can enhance the commercial viability of new patents.

KPI Depot is trusted by consulting, strategy, finance, and analytics teams at leading organizations worldwide, including those listed below.

Percentage of Revenue from Patented Products Benchmarks

We have 2 relevant benchmarks in our benchmarks database.

Browse the Top Benchmarked KPIs in Intellectual Property Strategy

Reading the Benchmarks for Percentage of Revenue from Patented Products

KPI Depot tracks two sources for this metric, and the first thing worth noticing is that neither one measures a company.

IPWatchdog's coverage of the joint European Union Intellectual Property Office and European Patent Office study reports the contribution of intellectual-property-intensive industries to the European economy over a multi-year window. The unit of analysis is an industry, several hundred of them, classified as IP-intensive by how much patent and other IP activity the firms in it show relative to other industries. The output is a share of an economy. An industry counted as patent-intensive still contains firms holding no patents at all.

The Patented Medicine Prices Review Board, a Canadian federal body, reports patented medicine sales as a share of all medicine sales in Canada. Here the unit of analysis is a medicine, and coverage is settled by a national patent register in a single price-regulated market for a single year. That is much closer to a product-level definition than the European study, and it remains a national market share rather than any company's revenue mix.

Three checks, then, before a customer trusts an external figure for this KPI.

One, the unit of analysis. Industry-level and national-market figures answer a question about an economy or a market. This metric asks about one company's revenue mix. The two are not interchangeable, and a figure lifted from one context into the other will be wrong by an unknowable amount.

Two, what counts as covered. A regulator's register, an industry classification, and a company's internal coverage mapping each decide the word patented differently. Only the third involves a legal judgment about which claims read on which product, and that judgment is where company-level figures actually diverge.

Three, jurisdiction and period. Both sources are single-jurisdiction. A patent granted in the European Union or in Canada says nothing about the same product's status elsewhere, and pharmaceutical patent economics inside a price-regulated market generalize poorly to other sectors.

OKRs That Use Percentage of Revenue from Patented Products

This KPI is named directly as a key result in the Intellectual Property Strategy KPI group's own OKR material, under the objective of aligning intellectual property work with business strategy so it produces commercial impact. That is its natural home. Sharing the objective are IP Strategy Alignment with Business Goals, IP Licensing Revenue, and IP Revenue Growth Rate: one qualitative alignment measure, one monetization channel that bypasses product revenue entirely, and one growth measure.

Written directionally, the key result reads: raise the share of revenue standing behind owned, granted patents in the core product lines, on a coverage definition fixed at the start of the cycle. That second clause does real work. Without it the key result can be met by loosening what counts as patented, which costs nothing and proves nothing. Freeze the coverage rule and name it in the OKR.

Pair the metric with IP Licensing Revenue deliberately rather than by habit. Those two can move in opposite directions for entirely good reasons, so an objective holding both keeps a team from quietly optimizing one at the other's expense.

The group's second worked objective, building a high-quality portfolio that strengthens competitive position, gives the metric a different role. Patent Quality Index, Patent Claim Breadth, and IP Portfolio Strength all assess the portfolio on its own terms. This metric asks whether any of that reached a paying customer. Used that way it is the check on an objective rather than the target of one, which is often the more honest placement for it.

The group's best-practice guidance says as much: tie IP metrics to business revenue measures so IP work is validated by market success instead of by portfolio statistics. Whatever direction a team commits to, commit for a full cycle, on a frozen definition, with known expiries forecast separately so a scheduled decline is never mistaken for a miss.

See OKR Examples for Intellectual Property Strategy

Free Whitepaper

Want to achieve performance excellence in Intellectual Property Strategy? Download our in-depth whitepaper: Definitive Guide to Intellectual Property Strategy KPIs.

Download the Free Guide

KPI Categories

This KPI is associated with the following categories and industries in our KPI database: